Ocular drug delivery is not a single formulation problem. It is a system design problem created by the layered anatomy of the eye, rapid clearance mechanisms, small dosing volumes, stringent sterility expectations, and low tolerance for irritation or visual disturbance. A platform that improves solubility but fails on comfort, dose reproducibility, or manufacturability has not solved the product problem.
The decision framework below is drawn from a review paper by Dr. Shikha P. Barman, Founder, President, and CEO of Integral BioSystems. It is written for teams choosing between a drop, a depot, an insert, and a device, and it argues that the choice should be made as an explicit trade study rather than as a downstream consequence of an available technology.
Why Ocular Drug Delivery Is a System Design Problem
Topical drops remain the least invasive and most familiar route, but precorneal loss and epithelial barriers constrain exposure, particularly beyond the anterior segment. Local injections and implants provide direct or sustained exposure while adding procedural burden and route-specific safety risks. Nanocarriers, in situ gels, inserts, microneedles, depots, and device-enabled systems widen the design space, and none of them removes the need for a strategy that starts with the target product profile.
Five commitments follow from that position:
- Define the anatomical target, the pharmacologic concentration, the onset, and the duration before selecting a carrier.
- Use the simplest platform capable of meeting the exposure requirement, and make added complexity earn its place through measurable product benefit.
- Treat comfort, sterility assurance, container and closure performance, particulate control, and dose delivery as core quality attributes rather than late-stage checks.
- Build an orthogonal translation chain linking physicochemical attributes to release, tissue exposure, pharmacodynamics, and clinically meaningful outcomes.
- Lock scalable unit operations and stability-indicating controls early enough that nonclinical and clinical lots represent the intended commercial product.
How Eye Anatomy Creates Route-Dependent Barriers
The ocular surface is protected by the tear film, blinking, nasolacrimal drainage, epithelial tight junctions, metabolic enzymes, and efflux transporters. These defenses remove foreign material quickly and limit transcorneal passage. The corneal epithelium favors lipophilic permeants, while the hydrophilic stroma resists highly lipophilic molecules, so a successful transcorneal candidate needs balanced properties or a delivery system that changes the effective transport behavior. The conjunctiva offers a larger and more permeable surface but is highly vascularized, which can divert drugs into systemic circulation. Reaching the posterior segment from a topical dose means overcoming long diffusion distances, scleral and choroidal clearance, and the blood-retinal barrier.
Each barrier has an engineering answer, and each answer has a cost. Tear dilution and turnover is addressed through mucoadhesion, viscosity, in situ gelling, and controlled drop volume. The corneal epithelium is addressed through prodrug design, permeation enhancement, nanocarrier interaction, or iontophoresis. The corneal stroma is addressed through balanced logD, cyclodextrins, micelles, and supersaturation control. Conjunctival vasculature is addressed through residence control, depot placement, and dose minimization. Blood-aqueous and blood-retinal barriers are addressed through local injection, implant, or targeted biologic and gene delivery.
Reported ocular bioavailability varies with molecule, formulation, species, sampling compartment, and endpoint, which is why a universal percentage is less useful than a mass balance mindset. Administered dose becomes retained dose, then permeated dose, then tissue exposure, then target engagement, then response. Each transition needs a fit-for-purpose assay and a predefined uncertainty, and that chain is the substance of ophthalmic formulation development services rather than an afterthought to them.
Comparing the Routes of Ocular Administration
Six routes cover most programs, and each carries a distinct trade:
- Topical suits the tear film, conjunctiva, cornea, and anterior chamber. It is noninvasive, familiar, and scalable but subject to rapid clearance, adherence limits, and constrained posterior exposure.
- Subconjunctival and periocular routes suit anterior and periocular tissues and selected posterior targets. They create a local depot and avoid the epithelial barrier, at the cost of injection burden, clearance, and tissue tolerability.
- Intracameral delivery suits the anterior chamber and the iris and ciliary body, giving direct controlled anterior exposure, with endothelial and pressure risks attached to the procedure.
- Intravitreal delivery suits the vitreous, retina, and choroid, with an established clinical pathway, offset by injection burden and risks including endophthalmitis, inflammation, pressure change, and retinal injury.
- Suprachoroidal delivery suits the choroid and retina with compartmentalized posterior exposure, requiring a specialized device, accommodating variable anatomy, and demanding procedural training.
- Systemic delivery suits bilateral or multisystem disease using conventional dosing, limited by blood-ocular barriers and systemic exposure.
The working rule is to choose the least invasive route that can reliably meet the tissue exposure requirement. If a topical program claims posterior segment delivery, that claim should be supported by quantitative tissue pharmacokinetics, spatial localization, systemic exposure controls, and mechanism-consistent pharmacodynamics. Mapping that decision across the available drug delivery routes early is cheaper than discovering a route mismatch after a formulation is locked.
Matching the Platform to the Exposure Requirement
Conventional Solutions, Suspensions, and Emulsions
Aqueous solutions offer simple manufacture, rapid release, and relatively straightforward characterization, but they require adequate solubility and chemical stability. Suspensions accommodate poorly soluble drugs and provide a dissolution-controlled input while creating particle size, redispersibility, dose uniformity, irritation, and device clogging risks. Emulsions and ointments improve loading of lipophilic drugs and residence time but can blur vision or reduce acceptability.
Residence Enhancing Systems and Inserts
Viscosity modifiers, mucoadhesive polymers, and stimuli-responsive gels retain the drug at the surface without making dispensing or vision unacceptable. The useful design window is narrow, because rheology at rest, shear thinning during blinking, drop formation, gelation kinetics, optical clarity, and preservative performance all interact. Inserts and drug-eluting contact lenses extend exposure further, and they bring placement, comfort, retention, dose dumping, and combination product considerations with them. The NanoM Wafer ocular insert sits in this class as a biodegradable insert placed in the lower conjunctival fornix.
Colloidal and Nanoscale Carriers
Liposomes, lipid nanoparticles, nanoemulsions, polymeric nanoparticles, nanomicelles, and nanosuspensions can improve apparent solubility, protect labile payloads, alter release, and enhance surface interaction. For oligonucleotides, proteins, and other biologics, carriers may also protect against degradation and support cell uptake. Those benefits have to be demonstrated against a simpler control, because colloidal systems introduce composition, particle size distribution, morphology, free versus associated drug, release, sterilization, aggregation, and long-term stability questions. Programs exploring this route typically begin with Lipid Nanoparticles services and a defined comparator rather than with a platform commitment.
Implants and Depots
Implants and depots deliver months-scale local exposure, with content uniformity, release, geometry, and degradation as the attributes that decide success. The frequent failure modes are dose dumping, migration, and the difficulty of reversing a dose once it is placed.
Starting With the Target Product Profile Instead of the Technology
The selection sequence runs from target tissue to molecule to exposure to product to patient, and it produces a route, a formulation, a device, and a control strategy as a single output. It should be run before formulation optimization and revisited whenever new pharmacokinetic, tolerability, manufacturing, or human factors data arrive. Its function is to convert an interesting technology into a falsifiable product hypothesis.
Five questions carry most of the weight. Which tissue and cell type must be exposed, which sets route and localization strategy. What concentration and time profile drives the effect, which decides immediate against sustained release. What dosing burden is acceptable, which decides dosage form and device. What safety margin is required, which decides dose, excipients, release rate, and reversibility. What commercial presentation is intended, which decides sterilization, container, and process.
Sterilization deserves particular attention because it is a design input rather than a final check. Terminal sterilization is generally preferred when product and container tolerate it. Otherwise, sterile filtration and aseptic processing require a formulation that passes the filter without unacceptable loss or size change, and a process designed for contamination control. Nanoparticles, suspensions, viscous systems, biologics, and implants may be incompatible with conventional filtration or heat, so the chosen method has to be justified by product and process data.
What This Means for Ophthalmic Development Teams
Three practical consequences follow for teams planning the next stage of an eye program:
- A formulation should not advance because a fresh laboratory sample performs well. It should advance when the intended composition, manufacturing process, sterilization strategy, container and closure system, and stability profile jointly support the clinical use case.
- Model selection should follow the unanswered product risk rather than convention. Rabbits are useful for topical tolerability and anterior segment work but may not predict human residence or posterior distribution directly. Rodents enable disease biology and genetic tools, while larger eyes better support devices, injections, imaging, and surgical procedures.
- An apparent exposure gain can mislead if it is caused by residual formulation on tissue surfaces, vascular contamination, assay cross-reactivity, or barrier damage. Tissue collection, washing, perfusion, matrix effects, recovery, limits of quantitation, and the distinction between intact payload and label should all be validated.
The central translational challenge is unchanged. A novel platform is valuable only when it produces a clinically relevant improvement that survives scale-up, sterilization, storage, administration, and real-world use. The most important choice in an ophthalmic program is not between conventional and advanced technologies; it is between an evidence-led product architecture and a technology-led formulation search.
Read the Full White Paper
This article summarizes Ophthalmic Drug Delivery, A Review, a white paper by Dr. Shikha P. Barman, Founder, President, and CEO of Integral BioSystems. To review the complete paper, including the barrier and lever table, the full route comparison, the platform attribute matrix, the translational evaluation stages, the CMC and regulatory workstream table, the six-phase development roadmap, and the reference list, download the full white paper (PDF).
Discuss Your Ocular Formulation Program
Whether the open question is which route can reach the target tissue, whether a topical claim will survive scrutiny, or how a sterilization strategy will interact with a colloidal system, Integral BioSystems supports ophthalmic programs from product hypothesis through IND-enabling work. Request a formulation consult to discuss your target tissue, your exposure requirement, and the route trade study that should come before formulation optimization.